<main class="html-publication" role="main" lang="en">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          
<div class="gem-c-organisation-logo brand--department-of-health">
    <a href="/government/organisations/uk-health-security-agency" class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color">
      <span class="gem-c-organisation-logo__name">UK Health<br>Security<br>Agency</span>
</a>
</div>
        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  

<div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
      <span class="govuk-caption-xl gem-c-title__context">
    Guidance
  </span>


  <h1 class="gem-c-title__text govuk-heading-xl">
    National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests
  </h1>
</div>
  <p class="publication-header__last-changed">Updated 2 February 2022</p>

  </header>



<div class="govuk-grid-row sidebar-with-body" data-module="sticky-element-container">
    <div class="govuk-grid-column-one-quarter-from-desktop contents-list-container">
        <nav class="gem-c-contents-list" aria-label="Contents" role="navigation" data-module="gem-track-click">
    <h2 class="gem-c-contents-list__title">
      Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#high-level-process" data-track-options="{&quot;dimension29&quot;:&quot;High-level process&quot;}" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" href="#high-level-process">High-level process</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#register-interest" data-track-options="{&quot;dimension29&quot;:&quot;\n1.  Register interest&quot;}" href="#register-interest" class="gem-c-contents-list__link govuk-link govuk-link--no-underline"><span class="gem-c-contents-list__number">1. </span><span class="gem-c-contents-list__numbered-text">Register interest</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-category="contentsClicked" href="#triage-and-initial-review" data-track-action="content_item 3" data-track-label="#triage-and-initial-review" data-track-options="{&quot;dimension29&quot;:&quot;\n2.  Triage and initial review&quot;}"><span class="gem-c-contents-list__number">2. </span><span class="gem-c-contents-list__numbered-text">Triage and initial review</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-label="#preliminary-evaluation" data-track-category="contentsClicked" data-track-action="content_item 4" data-track-options="{&quot;dimension29&quot;:&quot;\n3.  Preliminary evaluation&quot;}" href="#preliminary-evaluation"><span class="gem-c-contents-list__number">3. </span><span class="gem-c-contents-list__numbered-text">Preliminary evaluation</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-options="{&quot;dimension29&quot;:&quot;\n4.  Assay validation&quot;}" href="#assay-validation" data-track-category="contentsClicked" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 5" data-track-label="#assay-validation"><span class="gem-c-contents-list__number">4. </span><span class="gem-c-contents-list__numbered-text">Assay validation</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-options="{&quot;dimension29&quot;:&quot;\n5.  Independent evaluation&quot;}" href="#independent-evaluation" data-track-label="#independent-evaluation" data-track-category="contentsClicked" data-track-action="content_item 6" class="gem-c-contents-list__link govuk-link govuk-link--no-underline"><span class="gem-c-contents-list__number">5. </span><span class="gem-c-contents-list__numbered-text">Independent evaluation</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-label="#endorsement-by-the-tvg-and-publication-of-results" href="#endorsement-by-the-tvg-and-publication-of-results" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-options="{&quot;dimension29&quot;:&quot;\n6.  Endorsement by the TVG and publication of results&quot;}" data-track-category="contentsClicked" data-track-action="content_item 7"><span class="gem-c-contents-list__number">6. </span><span class="gem-c-contents-list__numbered-text">Endorsement by the TVG and publication of results</span></a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-category="contentsClicked" data-track-options="{&quot;dimension29&quot;:&quot;Appeals&quot;}" href="#appeals" data-track-action="content_item 8" data-track-label="#appeals" class="gem-c-contents-list__link govuk-link govuk-link--no-underline">Appeals</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-action="content_item 9" href="#products-in-the-pipeline" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-label="#products-in-the-pipeline" data-track-options="{&quot;dimension29&quot;:&quot;Products in the pipeline&quot;}" data-track-category="contentsClicked">Products in the pipeline</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-action="content_item 10" data-track-options="{&quot;dimension29&quot;:&quot;Evaluation concluded or paused&quot;}" data-track-category="contentsClicked" href="#evaluation-concluded-or-paused" data-track-label="#evaluation-concluded-or-paused">Evaluation concluded or paused</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-category="contentsClicked" href="#publication-of-results" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-label="#publication-of-results" data-track-action="content_item 11" data-track-options="{&quot;dimension29&quot;:&quot;Publication of results&quot;}">Publication of results</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a href="#evaluated-antibody-tests" data-track-label="#evaluated-antibody-tests" class="gem-c-contents-list__link govuk-link govuk-link--no-underline" data-track-category="contentsClicked" data-track-action="content_item 12" data-track-options="{&quot;dimension29&quot;:&quot;Evaluated antibody tests&quot;}">Evaluated antibody tests</a>

        </li>
    </ol>
</nav>
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button data-module="print-link" class="govuk-link govuk-body-s gem-c-print-link__button">Print this page</button>
</div>
    </div>

  <div class="print-wrapper">
    <div class="print-meta-data">
      <p>
  <img class="print-meta-data-licence" src="/assets/government-frontend/open-government-licence-min-e98134ae65ff5fe99a524d8c383350b3998f91c298dc24b36126e65f1656c578.png">
</p>
<p>
  © Crown copyright 2022
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/national-standardised-test-performance-process-for-manufacturers-of-sars-cov-2-virus-antibody-tests
</p>


    </div>
  </div>

  <div class="main-content-container">
    <div class="gem-c-govspeak-html-publication">
  
<div data-module="govspeak" class="gem-c-govspeak govuk-govspeak ">
    
    
      <div class="govspeak">
<div class="application-notice info-notice" aria-label="Information" role="note">
<p>This guidance only applies to SARS-CoV-2 (COVID-19) serology antibody tests. It outlines how the government will review and independently evaluate SARS-CoV-2 serodiagnostic antibody assays.</p>
</div>

<div role="note" class="application-notice help-notice" aria-label="Warning">
<p>A serodiagnostic antibody assay that successfully completes the standardised test performance process will not lead to a procurement or contract but will result in an independently evaluated serodiagnostic antibody assay.</p>
</div>

<h2>High-level process</h2>

<p>The standardised test performance process follows 6 key steps:</p>

<ol>
  <li>
    <p>Register interest</p>
  </li>
  <li>
    <p>Triage and initial review</p>
  </li>
  <li>
    <p>Preliminary evaluation</p>
  </li>
  <li>
    <p>Assay validation</p>
  </li>
  <li>
    <p>Independent evaluation by <abbr title="United Kingdom">UK</abbr> Health Security Agency (<abbr title="United Kingdom Health Security Agency">UKHSA</abbr>)</p>
  </li>
  <li>
    <p>Results endorsement by the Technical Validation Group (<abbr title="Technical Validation Group">TVG</abbr>) and publication of results</p>
  </li>
</ol>

<p>If you have any enquiries regarding this process, please email <a href="mailto:nibsc@dhsc.gov.uk" class="govuk-link">nibsc@dhsc.gov.uk</a>.</p>

<h2>
<span class="number">1. </span> Register interest</h2>

<p>Manufacturers of SARS-CoV2 (COVID-19) tests for antibody detection can register their interest in the national independent evaluation process if their test meets (or are intended to meet in the case of tests under development) the requirements of a relevant Medicines and Healthcare products Regulatory Agency (<abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr>) <a class="govuk-link" href="https://www.gov.uk/government/publications/how-tests-and-testing-kits-for-coronavirus-covid-19-work">Target Product Profile (<abbr title="Target Product Profile">TPP</abbr>)</a>.</p>

<div class="call-to-action">
<p>To register your interest in this process, email <a class="govuk-link" href="mailto:nibsc@dhsc.gov.uk">nibsc@dhsc.gov.uk</a>. Following registration, manufacturers will be sent a questionnaire and non-disclosure agreement (NDA) to complete.</p>
</div>

<p>Test manufacturers are required to complete the questionnaire for each test they want to supply. The form captures the main clinical and commercial information required to triage the large volume of offers received.</p>

<p>This process is designed to support manufacturers to develop high-quality serodiagnostic assays as part of our commitment to ensuring high-quality products are available to support the national Test and Trace programme. As a result, information should be provided directly from manufacturers to ensure that the technical information can be confirmed directly with the manufacturer.</p>

<div aria-label="Information" class="application-notice info-notice" role="note">
<p>For blood-based serodiagnostic, the steps outlined below apply.</p>
</div>

<div aria-label="Information" class="application-notice info-notice" role="note">
<p>For non-blood-based serodiagnostic assays, an alternative validation route will be created as required.</p>
</div>

<p>A manufacturer wishing to withdraw their device from the standardised test performance process at any stage should inform <a class="govuk-link" href="mailto:nibsc@dhsc.gov.uk">nibsc@dhsc.gov.uk</a>.</p>

<p>Please note that once a manufacturer has agreed to progress to the independent evaluation stage this will mean that they have agreed that the results of the independent evaluation will be published.</p>

<h3>Sharing of personally and commercially sensitive information</h3>

<p>By submitting your data, you are consenting to the information provided in this submission being shared with the relevant triage, review, validation and evaluation groups that form part of <abbr title="Department of Health and Social Care">DHSC</abbr>’s national test and trace programme.</p>

<p>The information provided will only be used for the above purpose and will not be shared with individuals or groups unconnected to the process.</p>

<p>Your data subject rights are in no way affected.</p>

<p><a href="https://www.gov.uk/government/organisations/department-of-health-and-social-care/about/personal-information-charter#department-of-health-and-social-care-data-protection-policy" class="govuk-link">Read the <abbr title="Department of Health and Social Care">DHSC</abbr> data protection policy</a></p>

<h2>
<span class="number">2. </span> Triage and initial review</h2>

<p>The completed registration information and any supporting documents will be reviewed by the Results Oversight Committee.</p>

<p>This triage and initial review is based on a review of the clinical and technical information provided by the manufacturer in the completed questionnaire including:</p>

<ul>
  <li>
    <p>the manufacturer holding ISO 13485:2016 covering the registered device</p>
  </li>
  <li>
    <p>product use and type</p>
  </li>
  <li>
    <p>target analyte</p>
  </li>
  <li>
    <p>specimen type, including equivalence between types as appropriate</p>
  </li>
  <li>
    <p>output result</p>
  </li>
  <li>
    <p>analytical and diagnostic sensitivity and specificity as per <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> <abbr title="Target Product Profile">TPP</abbr></p>
  </li>
  <li>
    <p>confirmation of known cross-reactivity</p>
  </li>
  <li>
    <p>regulatory status</p>
  </li>
  <li>
    <p>uniqueness of the device</p>
  </li>
</ul>

<p>Following the review, tests are deemed to be one of the following:</p>

<ul>
  <li>
    <p>aligned to the current national testing priority needs and progressed for completion of the standardised test performance for serodiagnostic antibody assays</p>
  </li>
  <li>
    <p>not aligned to the current national testing priority needs and held on file for review in case of any future changes to our testing needs</p>
  </li>
  <li>
    <p>do not currently have the performance and clinical data required to pass triage but where it is recommended that the organisation generates this data</p>
  </li>
</ul>

<div role="note" class="application-notice info-notice" aria-label="Information">
<p>Manufacturers should expect to receive an outcome within 2 weeks of submission of a completed questionnaire and NDA. This may be longer, subject to the volume of offers that we are reviewing.</p>
</div>

<h2>
<span class="number">3. </span> Preliminary evaluation</h2>

<p>Offers that are deemed by the Results Oversight Committee to have met the relevant criteria will be progressed for preliminary evaluation. Manufacturers will be contacted and invited to take part in further technical validation and/or in-service evaluation.</p>

<p>If the manufacturer wishes to proceed, they will be required to:</p>

<ul>
  <li>
    <p>complete and sign a Material Transfer Agreement (<abbr title="material transfer agreement">MTA</abbr>) with the National Institute for Biological Standards and Control</p>
  </li>
  <li>
    <p>procure from <abbr title="National Institute for Biological Standards and Control">NIBSC</abbr> the British Common Verification Panel, a pre-diluted series of <abbr title="National Institute for Biological Standards and Control">NIBSC</abbr>’s standard for SAR-CoV-2 antibodies, external quality control</p>
  </li>
  <li>
    <p>conduct the preliminary evaluation tests in its laboratory using the same batch of devices for all stages</p>
  </li>
  <li>
    <p>provide the results of the preliminary evaluation to <abbr title="National Institute for Biological Standards and Control">NIBSC</abbr> for analysis using the <a class="govuk-link" href="https://extranet.who.int/pqweb/vitro-diagnostics/performance-evaluation" rel="external">World Health Organization (<abbr title="World Health Organization">WHO</abbr>) scoring system</a></p>
  </li>
</ul>

<h2>
<span class="number">4. </span> Assay validation</h2>

<p>Results and analysis from the preliminary evaluation that are deemed by the Results Oversight Committee to have met the relevant <abbr title="Target Product Profile">TPP</abbr> and align to the current needs of the national Test and Trace programme will be progressed for assay validation. Manufacturers will be contacted and invited to take part in further technical validation and/or in-service evaluation.</p>

<p>If the manufacturer wishes to proceed, they will be required to:</p>

<ul>
  <li>
    <p>complete and sign a further <abbr title="material transfer agreement">MTA</abbr> with <abbr title="National Institute for Biological Standards and Control">NIBSC</abbr></p>
  </li>
  <li>
    <p>procure from <abbr title="National Institute for Biological Standards and Control">NIBSC</abbr>: Common Validation Panel</p>
  </li>
  <li>
    <p>conduct the assay validation tests in its laboratory using the same batch of devices for all stages</p>
  </li>
  <li>
    <p>provide the results of the assay validation tests to <abbr title="National Institute for Biological Standards and Control">NIBSC</abbr> for analysis using the <a href="https://www.who.int/diagnostics_laboratory/evaluations/alter/protocols/en/" rel="external" class="govuk-link"><abbr title="World Health Organization">WHO</abbr> scoring system (see the HIV and HBsAg protocols)</a></p>
  </li>
</ul>

<h2>
<span class="number">5. </span> Independent evaluation</h2>

<p>Results and analysis from the assay validation that are deemed by the Results Oversight Committee to have met the relevant <abbr title="Target Product Profile">TPP</abbr> will be progressed for independent evaluation by <abbr title="United Kingdom Health Security Agency">UKHSA</abbr>. Manufacturers will be contacted and invited to take part in further technical validation and/or in-service evaluation.</p>

<p>If the manufacturer wishes to proceed, they will be expected to:</p>

<ul>
  <li>
    <p>complete a testing and evaluation agreement with <abbr title="United Kingdom Health Security Agency">UKHSA</abbr></p>
  </li>
  <li>
    <p>provide 750 product test kits/assays from a single batch and all required consumables and reagents free of charge for independent evaluation</p>
  </li>
  <li>
    <p>provide <abbr title="United Kingdom Health Security Agency">UKHSA</abbr> (Colindale) with the technical validation and additional relevant technical information to support the independent evaluation activity including training if needed</p>
  </li>
  <li>
    <p>provide relevant legal documents to support the independent evaluation and <abbr title="non-disclosure agreements">NDAs</abbr> where needed</p>
  </li>
  <li>
    <p>agree to the results of the process being made publicly available</p>
  </li>
  <li>
    <p>confirm that they have immediate availability of sufficient testing kits to allow further independent evaluation and can provide sufficient product volumes, including consumables and reagents, with a lead time of less than one month from order if required</p>
  </li>
</ul>

<div role="note" aria-label="Information" class="application-notice info-notice">
<p>Manufacturers should expect to receive an outcome within 4 weeks of UKHSA receiving a completed agreement and the requisite test kits, consumables and training as appropriate. This may be longer subject to the volume of offers that we are reviewing.</p>
</div>

<h2>
<span class="number">6. </span> Endorsement by the <abbr title="Technical Validation Group">TVG</abbr> and publication of results</h2>

<p>The outcome of the independent evaluation will be reviewed by the Results Oversight Committee with results and recommendations submitted to the <abbr title="Technical Validation Group">TVG</abbr>, part of <abbr title="Department of Health and Social Care">DHSC</abbr>, for endorsement.</p>

<p>The <abbr title="Technical Validation Group">TVG</abbr> includes a range of experts in technologies, viral testing and infectious disease, including representatives from the:</p>

<ul>
  <li>
    <p>central validation labs (including <abbr title="United Kingdom Health Security Agency">UKHSA</abbr> Frimley and Cumbria)</p>
  </li>
  <li>
    <p>CONDOR (COVID-19 National Diagnostic Research and Evaluation Platform)</p>
  </li>
  <li>
    <p>Innovate <abbr title="United Kingdom">UK</abbr></p>
  </li>
  <li>
    <p>academia professional body (Royal College of Pathology)</p>
  </li>
  <li>
    <p><abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr></p>
  </li>
</ul>

<p>This group replaces all of the functions of the previous Viral Detection (molecular) Tests Group (VTAG) and, for new serology technologies, the work previously undertaken by the New Tests Advisory Group (NTAG).</p>

<p><abbr title="Technical Validation Group">TVG</abbr> reviews the outcome of all of the validation and evaluations and makes recommendations to the wider COVID-19 Test, Trace, Contain and Enable (TTCE) programme on the suitability of the solutions and technologies.</p>

<div class="application-notice help-notice" aria-label="Warning" role="note">
<p>A serodiagnostic antibody assay that successfully completes the standardised test performance process will not lead to a procurement or contract but will result in an independently evaluated serodiagnostic assay.</p>
</div>

<h2>Appeals</h2>

<p>If a manufacturer or a distributor acting on their instruction disagrees with the findings or decisions of the Results Oversight Committee at any stage, they may appeal by emailing the Test and Trace independent complaints team at <a href="mailto:ttsupplierescalation@dhsc.gov.uk" class="govuk-link">ttsupplierescalation@dhsc.gov.uk</a> with details of their objection and providing supporting data.</p>

<h2>Products in the pipeline</h2>

<p>The following table provides a snapshot of the number of products currently in the standardised test performance process pipeline for SARS-CoV-2 virus antibody tests as at 6 January 2022 and their status:</p>

<table>
  <thead>
    <tr>
      <th scope="col">Status</th>
      <th scope="col" style="text-align: right">Number of tests</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th scope="row">Registered interest</th>
      <td style="text-align: right">69</td>
    </tr>
    <tr>
      <th scope="row">Currently being evaluated</th>
      <td style="text-align: right">31</td>
    </tr>
    <tr>
      <th scope="row">Evaluation concluded or paused</th>
      <td style="text-align: right">12</td>
    </tr>
    <tr>
      <th scope="row">Evaluated technology</th>
      <td style="text-align: right">0</td>
    </tr>
    <tr>
      <th scope="row">Total</th>
      <td style="text-align: right">112</td>
    </tr>
  </tbody>
</table>

<h2>Evaluation concluded or paused</h2>

<p>The following table provides a snapshot as at 15 March 2021 of the antibody tests that have concluded or paused the standardised test performance process for SARS-CoV-2 virus antibody tests.</p>

<table>
  <thead>
    <tr>
      <th scope="col">Ref</th>
      <th scope="col">Primary use location</th>
      <th scope="col">Product type</th>
      <th scope="col">High-level justification</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>0000</td>
      <td>For example, professional use</td>
      <td>For example, lateral flow device</td>
      <td>For example, test withdrawn by manufacturer</td>
    </tr>
  </tbody>
</table>

<h2>Publication of results</h2>

<p>We will publish links to antibody tests that have been reviewed here.</p>

<h2>Evaluated antibody tests</h2>

<p>We will publish links to the evaluation reports for each of these antibody tests here.</p>

</div>


</div>
</div>
  </div>

  <div data-sticky-element="" class="sticky-element">
    <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg height="17" xmlns="http://www.w3.org/2000/svg" width="13" class="app-c-back-to-top__icon" focusable="false" viewBox="0 0 13 17">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

    <div class="sticky-element__print-link">
      
<div class="gem-c-print-link govuk-!-display-none-print govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button data-module="print-link" class="govuk-link govuk-body-s gem-c-print-link__button">Print this page</button>
</div>
    </div>
  </div>
</div>

    </main>